Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD)

Starting soon

Conditions studied: Hyperuricemia and MAFLD

In brief

Due to the established correlation between serum uric acid (SUA) levels and metabolic associated fatty liver disease (MAFLD), this study aims to screen for hyperuricemia in all patients diagnosed with MAFLD. The ultimate goal is to support the management of MAFLD and improve patients' quality of life by reducing both morbidity and mortality.

Key facts

Study ID

NCT07053709

Run by

Assiut University

People needed

200

Starts

2026-11-01

Expected to finish

2027-11-01

Last updated by the study team

2026-01-13

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged over 18 years.
• Diagnosis of MAFLD based on abdominal ultrasonography or other validated imaging techniques.

You may not qualify if…

• Patients aged 18 years or younger.
• Pregnant individuals.
• Presence of any malignancy.
• Diagnosis of type 1 diabetes mellitus (T1DM).
• Patients with fatty liver disease who have previously undergone bariatric surgery.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.